期刊
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
卷 23, 期 7, 页码 1210-1220出版社
AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2011070751
关键词
-
资金
- National Institutes of Health [DK35124, DK72517, DK86125, EB00415, HL73856, EY13574]
- Cystic Fibrosis Foundation
Urea transport (UT) proteins facilitate the concentration of urine by the kidney, suggesting that inhibition of these proteins could have therapeutic use as a diuretic strategy. We screened 100,000 compounds for UT-B inhibition using an optical assay based on the hypotonic lysis of acetamide-loaded mouse erythrocytes. We identified a class of triazolothienopyrimidine UT-B inhibitors; the most potent compound, UTBinh-14, fully and reversibly inhibited urea transport with IC50 values of 10 nM and 25 nM for human and mouse UT-B, respectively. UTBinh-14 competed with urea binding at an intracellular site on the UT-B protein. UTBinh-14 exhibited low toxicity and high selectivity for UT-B over UT-A isoforms. After intraperitoneal administration of UTBinh-14 in mice to achieve predicted therapeutic concentrations in the kidney, urine osmolality after administration of 1-deamino-8-D-arginine-vasopressin was approximately 700 mosm/kg H2O lower in UTBinh-14 treated mice than vehicle-treated mice. UTBinh-14 also increased urine output and reduced urine osmolality in mice given free access to water. UTBinh-14 did not reduce urine osmolality in UT-B knockout mice. In summary, these data provide proof of concept for the potential utility of UT inhibitors to reduce urinary concentration in high-vasopressin, fluid-retaining conditions. The diuretic mechanism of UT inhibitors may complement the action of conventional diuretics, which target sodium transport.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据